Item 7.01 Regulation FD Disclosure.

On November 16, 2022, Inhibrx, Inc. (the "Company") posted an updated copy of its corporate slide presentation to the "Investors" tab of its website at www.inhibrx.com. These slides are also attached to this Current Report on Form 8-K as Exhibit 99.1. The Company from time to time presents and/or distributes to the investment community at various industry and other conferences slide presentations to provide updates and summaries of its business. It undertakes no obligation to update, supplement or amend the materials attached hereto as Exhibit 99.1.




Item 8.01 Other Events.

On November 16, 2022, the Company issued a press release announcing updated efficacy and safety data from the Phase 1 INBRX-109 expansion cohorts for the treatment of chondrosarcoma.

The full text of the Company's press release regarding this announcement is filed as Exhibit 99.2 to this Current Report on Form 8-K and incorporated herein by reference.

The information in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.



(d) Exhibits.

 Exhibit No.      Description
99.1                Corporate Presentation
99.2                Press Release issued by Inhibrx, Inc. on November 16, 2022

© Edgar Online, source Glimpses